Clinical Trial Update: An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating APX001 (fosmanogepix) for candidemia and invasive candidiasis caused by Candida auris; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Invasive Candidiasis

Drugs mentioned

• APX001 (fosmanogepix)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Candidemia, Invasive Candidiases | Phase 2 | Status: COMPLETED | Results posted: 2023-01-09